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Background: Artemether-lumefantrine (AL) was adopted as first-line treatment for uncomplicated malaria in Kenya
in 2006. Monitoring drug efficacy at regular intervals is essential to prevent unnecessary morbidity and mortality.
The efficacy of AL and dihydroartemisinin-piperaquine (DP) were evaluated for the treatment of uncomplicated
malaria in children aged six to 59 months in western Kenya.
Methods: From October 2010 to August 2011, children with fever or history of fever with uncomplicated
Plasmodium falciparum mono-infection were enrolled in an in vivo efficacy trial in accordance with World Health
Organization (WHO) guidelines. The children were randomized to treatment with a three-day course of AL or DP
and efficacy outcomes were measured at 28 and 42 days after treatment initiation.
Results: A total of 137 children were enrolled in each treatment arm. There were no early treatment failures and all
children except one had cleared parasites by day 3. Polymerase chain reaction (PCR)-uncorrected adequate clinical and
parasitological response rate (ACPR) was 61% in the AL arm and 83% in the DP arm at day 28 (p = 0.001). PCR-corrected
ACPR at day 28 was 97% in the AL group and 99% in the DP group, and it was 96% in both arms at day 42.
Conclusions: AL and DP remain efficacious for the treatment of uncomplicated malaria among children in western
Kenya. The longer half-life of piperaquine relative to lumefantrine may provide a prophylactic effect, accounting for the
lower rate of re-infection in the first 28 days after treatment in the DP arm.Background
Resistance to anti-malarials by Plasmodium falciparum
has been an ongoing global public health concern since
chloroquine resistance emerged in the 1960s [1]. Drug
pressure is considered a major factor driving parasite
resistance, as a result of the increased availability of
medications in the public and private sectors, increased
prevalence of sub-therapeutic drug concentrations, and
counterfeit medications containing inadequate amounts
of active ingredients, among other factors.* Correspondence: aartiagarwal@hotmail.com
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reproduction in any medium, provided the orIn Kenya, chloroquine was first-line treatment for un-
complicated P. falciparum malaria until 1998, despite the
presence of high levels of chloroquine resistance since the
early 1990s [2]. In 1998, sulphadoxine-pyrimethamine
(SP) was adopted as first-line treatment, but resistance
rapidly emerged. Both sulphadoxine and chloroquine have
long half-lives and consequent prolonged parasite expos-
ure to subtherapeutic drug levels, which can contribute
to resistance.
Artemisinins, the newest class of anti-malarials, have
a very short half-life (<8 hours) and rapidly reduce para-
site burden; their use in combination with other anti-
malarials decreases the chance of resistance emergence
[3]. However, artemisinin resistance has developed
along the Thai-Cambodian border, likely due to its usel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Artemisinin-based combination therapy (ACT) has super-
ior efficacy and the potential to prevent drug resistance by
incorporating a partner drug to enhance parasite clearance.
ACT has been adopted as first-line treatment in most
malaria-endemic countries [5]. Artemether-lumefantrine
(AL), a highly effective ACT, is commonly used in many
African countries as first-line treatment [6]. In 2004, Kenya
adopted AL as first-line malaria treatment, but it was not
widely implemented until 2006 [7].
Dihydroartemisinin-piperaquine (DP), another ACT
regimen, has been studied in East Africa as an alterna-
tive to AL [8-10]. Its advantages over AL include once-
daily dosing and a longer half-life of the partner drug,
which may prevent re-infection in areas of intense mal-
aria transmission. Studies have shown equivalent safety
and efficacy profiles for DP and AL [10-12]. In 2010, DP
was adopted as second-line treatment for uncomplicated
P. falciparum malaria in Kenya.
Regular monitoring of anti-malarial efficacy is essential
to better inform national malaria policies [13]. This study
was conducted in western Kenya to determine if AL re-
mains efficacious for the treatment of uncomplicated mal-
aria after five years of its implementation and to evaluate
the efficacy of DP in this population.Methods
Study site and enrolment
This study was conducted between October 2010 and
August 2011 at Siaya District Hospital (SDH) in Nyanza
Province, western Kenya. This region is holoendemic for
P. falciparum with high malaria transmission and two sea-
sonal peaks, April to July and November to December.
The entomological inoculation rate (EIR) in this area, his-
torically around 300 infectious bites per person per year,
has recently been estimated to be ten infectious bites per
person per year (Gimnig J, pers comm). Study subjects
were recruited from the outpatient paediatric department
of SDH, which serves approximately 100 patients per day.
Subjects
Children aged six to 59 months with P. falciparum
mono-infection were enrolled. Additional inclusion cri-
teria were axillary temperature ≥37.5°C or history of
fever in the previous 48 hours, weight ≥5.0 kg, parasit-
aemia 1-200,000 asexual forms per μL (initially 2,000-
200,000 but protocol amended in January 2011 to include
any parasitaemia <200,000 as these drug regimens are
used to treat patients with any level of parasitaemia in
Kenya), residence within 10 km of SDH, and written in-
formed consent by caregiver. Subjects were excluded
if any of the following were present: lethargy, convulsions,
inability to drink, persistent vomiting, symptoms ofsevere malaria, severe malnutrition (weight-for-age ≤3
standard deviations below the mean for gender
according to World Health Organization (WHO) stan-
dards), severe anaemia (haemoglobin (Hb) <5 g/dl),
known hypersensitivity to study drugs, presence of
febrile illness other than malaria (e.g. measles, pneu-
monia), presence of chronic medical conditions, treat-
ment with any anti-malarial in the previous two weeks,
or previous enrolment in any malaria study.
Ethical considerations
This study received ethical clearance from the US Centers
for Disease Control and Prevention (CDC, Atlanta, USA)
and the Kenya Medical Research Institute (KEMRI,
Nairobi, Kenya). Written informed consent was obtained
from caregivers of enrolled subjects and a long-lasting
insecticide-treated bed net (ITN) was provided to enrolled
subjects.
Clinical and laboratory procedures
This was a 42-day, open-label in vivo trial [14]. Initial
screening was offered to patients with fever or history of
fever. Caregivers were then asked about interest in study
participation. After consenting patients were screened for
inclusion criteria, a rapid diagnostic test (RDT) (SD
Bioline malaria Pf/pan, Standard Diagnostics Inc, Yongin,
South Korea) for malaria and Hb testing (Hemocue® Hb
201+, Hemocue AB, Angelholm, Sweden) were performed.
If the RDT was positive and Hb was ≥5.0 g/dL, two thick
and thin blood films were collected to assess parasitaemia
and confirm malaria species. Blood films were read inde-
pendently by two microscopists by counting the number
of asexual parasites against 500 white blood cells (WBCs).
Slides were considered to be negative only after examining
fields containing 1,000 WBCs. The geometric mean of the
two readings was considered in the analyses. Slides with
parasite densities discordant by more than 50% or with
positive and negative results were re-examined by a third
microscopist; the mean of the third read and the closest of
the first two slides was considered final. All microscopists
were blinded to the treatment arm and were certified
as expert readers through a quality assurance programme
at the South African National Institute for Communicable
Diseases.
Caregivers of enrolled children were interviewed and
children were examined by a study clinician. Children
were block randomized in fixed blocks of ten to treatment
with AL (Coartem®; Novartis, Basel, Switzerland) or DP
(DuoCotexin®; Holley-Cotec Pharmaceuticals, Beijing,
China). Samples of the AL and DP used in this study were
sent to CDC laboratories for quality testing using high-
performance liquid chromatography (HPLC) (Agilent
Technologies, Waldbronn, Germany). Both treatments
were co-formulated, fixed-dose ACT regimens and were
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study clinic (except AL evening doses) for three consecu-
tive days. AL tablets, consisting of 20 mg of artemether and
120 mg lumefantrine, were administered twice daily
according to patient weight: 5-14 kg: one tablet per dose;
weight 15-24 kg: two tablets per dose; weight 25-34 kg:
three tablets per dose. Morning doses were given with milk
and directly observed in the study clinic. Caregivers were
given evening doses to administer at home with food or
milk. DP tablets, consisting of 20 mg dihydroartemisinin
and 160 mg of piperaquine phosphate, were administered
once daily by study staff according to patient weight: 5-6
kg: one-half tablet daily; 7-9 kg: one tablet daily; 10-14 kg:
two tablets on day 0, then one tablet on days 1 and 2; 5-19
kg: two tablets daily. A full dose was re-administered if the
patient vomited within 30 min or a half dose if vomiting oc-
curred between 31 and 60 min. Patients with vomiting
within 30 min of the second dose were referred for paren-
teral treatment and withdrawn from the study.Follow up
Children were followed for 42 days and asked to return on
days 1, 2, 3, 7, 14, 21, 28, 35, and 42 following enrolment,
as well as any day if ill. The study clinic was open daily
during regular hours; study personnel provided after-
hours care at SDH. A clinical assessment was performed
and blood smears were collected at each study visit. Hb
levels were measured on days 0, 7, 14, 28, and 42. A filter
paper blood spot was collected on days 0, 3, and 7 and in
case of suspected treatment failure for molecular analysis.
Adverse events were investigated and addressed.Outcomes
Efficacy was assessed by clinical and parasitological out-
comes using WHO definitions [14]. Children were classi-
fied as early treatment failure (ETF) if any of the following
criteria were met: development of severe malaria by day 3,
day 2 parasitaemia > day 0 parasitaemia, presence of para-
sites on day 3 with axillary temperature ≥37.5°C, or day 3
parasitaemia >25% of day 0 parasitaemia. Children not
meeting ETF criteria with P. falciparum parasitaemia oc-
curring between day 7 and 28 or 42 without fever were
classified as late parasitological failure (LPF). Those with
fever occurring between day 4 and day 28 or day 42 with
parasitaemia were classified as late clinical failure (LCF). If
no failure was recorded by day 28 or day 42, the outcome
was classified as adequate clinical and parasitological re-
sponse (ACPR). All treatment failures with uncomplicated
malaria were treated with AL and treatment failures with
severe malaria were treated with parenteral quinine.
Follow-up ended once a study subject met one of the four
classification criteria: ETF, LPF, LCP or ACPR.Molecular analysis
To differentiate between recrudescence and re-infection, a
genotypic analysis based on merozoite surface protein-2
(msp2), glutamate-rich protein (glurp), and merozoite
surface protein-1 (msp1) was performed by PCR using
filter-paper blood spots [15]. Recrudescence was defined
as at least one identical allele for each of the three markers
(msp2, glurp, and msp1) in the pre- and post-treatment
samples.
Statistical analysis
Primary efficacy outcomes included day 28 and day 42
ACPR, both PCR-corrected and PCR-uncorrected for each
ACT regimen. Secondary outcomes included haematologic
response, rates of fever clearance and parasite clearance by
day 3, rates of ETF, LPF and LCF. Assuming a PCR-
corrected ACPR of 95% and 20% loss to follow up at 42 days,
a sample size of 137 children per study arm was chosen, 274
children in total; this allowed for a precision rate of +/- 4.5%
at a 5% significance level. This study was not powered to de-
tect a difference in efficacy between treatment arms.
Study forms were scanned into a Microsoft Access 2000
(Microsoft, Redmond, USA) database. Statistical analysis
was performed using SAS® 9.2 (SAS Institute, Cary, USA).
Per protocol (PP) analysis of outcomes excluded those
children withdrawn from the study for any reason.
Intention-to-treat (ITT) analysis was performed using sur-
vival analysis. Kaplan-Meier curves were estimated for
both 28 and 42 days of follow up; the log-rank test was
used for comparing the curves. For ITT analysis, all with-
drawals, losses to follow up and treatment failures were
censored on the last day of follow up. Comparisons were
made using χ2 test for categorical variables and Student’s
t-test or Wilcoxon rank-sum test (for non-parametric
data) for continuous variables. A two-sided p-value <0.05
was considered statistically significant.
Results
Baseline characteristics
A total of 669 children with fever or history of fever were
screened (Figure 1). Among those, 420 (63%) were RDT-
positive and 324 (77%) of RDT-positive children had
microscopy-confirmed P. falciparum mono-infection. Of
these remaining 324 eligible children, 50 (15%) did not
meet other inclusion criteria or did not give consent. Two
hundred and seventy-four children were enrolled in the
study, 137 in each arm. Among those enrolled, 224 were
included in the day 42 analysis, 111 in the AL arm and
113 in the DP arm. Baseline characteristics of the children
enrolled in the two arms were similar (Table 1). The per-
centage of children withdrawn from analysis was similar
between the two arms, 18.2% in AL arm and 17.5% in the
DP arm (p = 0.88). Reasons for withdrawal are shown
in Figure 1.
Figure 1 Trial profile, western Kenya, 2011. Legend: RDT: Rapid diagnostic test for malaria; f/u: follow up; neg: negative.
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No ETF was observed in either treatment arm (Table 2).
Follow up was completed for 116 children in each arm up
to day 28. PCR-uncorrected ACPR was 61% in the AL arm
and 83% in the DP arm (p = 0.001). PCR-uncorrected re-
sults showed day 28 LCF and LPF were 11% and 28% in
the AL arm, respectively; in the DP arm, day 28 LCF and
LPF were 3% and 14%, respectively. PCR analysis revealed
the majority of LCF and LPF cases in both arms were due
to re-infection, 34 (92%) of 37 in the AL arm and 18 (95%)
of 19 in the DP arm. However, the re-infection rate by day
28 in the DP arm was significantly lower than that of the
AL arm (p = 0.03). At day 28, PCR-corrected ACPR was
97% for AL and 99% for DP (p = 0.5). The nine children
for whom PCR results were missing due to lost filter-paperTable 1 Baseline characteristics of children upon enrolment f
piperaquine (DP), western Kenya 2011
Characteristic AL (n = 13
Mean age (months) 36.1 (33.8–
Male (%) 55
Mean weight (kg) 13.3 (12.8–
Mean axillary temperature (°C) 37.6 (37.4–
Mean haemoglobin (g/dL) 9.7 (9.4–10
Geometric mean day 0 parasite density (parasites/ μL) (range) 45,168 (34samples were excluded from the PCR-corrected analysis
(eight from the AL arm and one from the DP arm).
For day 42, analysis was completed for 111 children in
the AL arm and 113 children in the DP arm. The PCR-
uncorrected ACPR was 44% for the AL arm and 54% for
the DP arm (p = 0.14). PCR-uncorrected results showed
that the day 42 LCF and LPF were 18% and 37% in the AL
arm, respectively; while LCF was 10% and LPF was 36% in
the DP arm. The re-infection rate was similar for the two
arms at day 42 (p = 0.7). After PCR correction, ACPR for
both arms was 96%. Similarly, the children for whom PCR
results were missing were excluded from analysis (ten in
AL arm and four in DP arm).
To ensure the results of the PCR-corrected analysis
were not biased by missing samples, sensitivity analysesor artemether-lumefantrine (AL) and dihydroartemisinin-
7) (95% CI) DP (n = 137) (95% CI) p-value
38.5) 33.5 (31.1–35.9) 0.11
57 0.9
13.8) 13.0 (12.5–13.4) 0.3
37.8) 37.7 (37.5–38.0) 0.35
.0) 9.9 (9.7–10.2) 0.28
,506–47,190) (10–148,027) 49,248 (35,188–52,544) (54–166,584) 0.49
Table 2 Clinical and parasitological response rates for artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine (DP) using per protocol analysis, western Kenya 2011
Outcome AL DP p-
value% (95% CI) % (95% CI)
Early treatment failure 0% (0%–3%) (0/137) 0% (0%–3%) (0/137) 1
Day 3 parasite clearance 99% (96%–99%) (130/131) 100% (97%–100%) (126/126) 0.34
Day 28 PCR-uncorrected ACPR* 61% (52%–70%) (71/116) 83% (75%–89%) (96/116) 0.001
Day 28 PCR-corrected ACPR** 97% (92%–99%) (105/108) 99% (95%–100%) (114/115) 0.48
Day 42 PCR-uncorrected ACPR 44% (35%–54%) (49/111) 54% (45%–63%) (61/113) 0.14
Day 42 PCR-corrected ACPR 96% (90%–99%) (97/101) 96% (91%–99%) (105/109) 0.26
*Polymerase chain reaction-uncorrected adequate clinical and parasitological response.
**Polymerase chain reaction-corrected adequate clinical and parasitological response.
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due to re-infection and all were due to recrudescence,
resulting in a range of PCR-corrected ACPR. For day 28,
the maximum ranges of PCR-corrected ACPR for the
treatment arms are 91-97% (95% CI: 85-100%) in the AL
arm and 98-99% (95% CI: 96-100%) in the DP arm. For
day 42, ACPR would be 87-96% (95% CI: 81-100%) in the
AL arm and 92-96% (95% CI: 87-100%) in the DP arm.
At day 28, the survival analysis using the ITT definition
demonstrated a PCR-uncorrected cure rate of 67% for AL
and 85% for DP (p = 0.0004) (Figure 2). At day 42, the
PCR-uncorrected cure rates were 55% for AL and 62% for
DP (p = 0.22). The PCR-corrected cure rates at day 28
were 98% for AL and 99% for DP (p = 0.28). At day 42,
PCR-corrected cure rates were 97% for both drugs.
Laboratory outcomes
Treatment with either AL or DP resulted in rapid parasite
clearance. Although >75% of children in both arms
remained parasitaemic on day 1, only four (3%) and five
(4%) children remained parasitaemic on day 2 in the AL
and DP arms, respectively. One child in the study












Figure 2 Survival curve of enrolled children by PCR-uncorrected data
(ITT) analysis.children were afebrile by day 1 in both treatment arms.
Mean Hb of children who were not re-infected increased
from a baseline of 9.8 g/dL to 11.6 g/dL at day 42, whereas
the mean Hb of those re-infected increased from a base-
line of 9.9 g/dL to 11.1 g/dL on the last study day (p = 0.9).
The change in Hb from baseline to the study endpoint
was similar among the two study arms. Drug samples
tested for quality assurance contained adequate concen-
trations of active ingredients.
Adverse events
There were three children in the DP arm who vomited the
drug twice following enrolment and were referred for al-
ternative treatment. The rates of vomiting for the first
dose of medication were similar for AL and DP (3.7% and
4.9%, respectively) and not associated with age.
Three enrolled children developed severe malaria
more than 28 days after treatment; two in the AL arm
and one in the DP arm. These children were hospitalized
for parenteral treatment. These outcomes are attribut-
able to re-infection (confirmed by PCR analysis), not
poor efficacy of treatment regimens. All children recov-





, western Kenya 2011. Legend: This graph is using intention to treat
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Both AL and DP are efficacious in treating uncomplicated
P. falciparum malaria in children in western Kenya. Recur-
rent parasitaemia among children under five years is fre-
quent in this area despite high coverage with ITNs (70%
household ownership and 42% usage in children under
five years) [16] and is mostly secondary to re-infection
with P. falciparum. As seen in other African countries, re-
current parasitaemia occurs significantly more frequently
in those children treated with AL in the first 28 days
[8,9,11]. This is likely due to the longer half-life of the
piperaquine component of DP, which provides long-
lasting prophylactic effect. This study was not powered to
compare the efficacy of the two drug regimens; however,
there was a significant difference in re-infection at day 28
between the two groups.
Data from similar studies conducted in western Kenya
from 2005 to 2009 assessing the efficacy of AL and DP
had similar results. Data collected in 2005 on children
with uncomplicated malaria and treated with AL showed
PCR-uncorrected ACPR at day 28 of 71% and at day 42
of 41%, compared to 61% and 44% in this study [17].
However, the high numbers of recurrent parasitaemia
were likely due to re-infection and not recrudescence, as
it was the case in this and other studies [18]. A smaller
study conducted in 2007, showed that only one (1.5%)
out of 67 patients had recurrent parasitaemia at day 28
after treatment with AL and no episodes of recurrent
parasitaemia were detected at day 28 in the DP group
[19]. When comparing these data to the higher rates of
recurrent parasitaemia in our study, we do not believe it
is due to declining drug efficacy, but rather to the high
frequency of re-infection with P. falciparum in children
in the study area. Lastly, data collected in 2009 in the
Mbita region of western Kenya had similar PCR-
corrected ACPR in the AL group (98.6% at day 28 and
97.2% at day 42) as what was observed in this evaluation,
which further demonstrates the continued efficacy of AL
in the region [18].
There is growing concern about the emergence of ar-
temisinin resistance, signalled by delayed parasite clear-
ance, as observed in Southeast Asia [20]. One recent
study from the Kenyan coast reports decreased parasite
clearance rates in those treated with ACT since 2006
[21]. This study showed that although over 75% of
children remained parasitaemic on day 1, over 95% had
cleared parasitaemia by day 2, and only one child had
parasites on day 3. These clearance rates are similar to
those seen in an efficacy study with AL conducted in
this region in 2006 [22]. As WHO defines suspected ar-
temisinin resistance as ≥10% of cases with parasitaemia
at day 3 after ACT treatment initiation [23], this study
provides no evidence to suggest artemisinin resistance
in western Kenya.Although the annual EIR in western Kenya has de-
creased dramatically, from 300 infectious bites per person
per year in 1990 [24] to ten in 2010, malaria prevalence
during the peak transmission season in children under five
years of age remains high at 42% (KEMRI/CDC, unpub-
lished data) [25]. A previous study demonstrated that in
several areas in Africa with annual EIRs in the range of
one to ten infectious bites per person per year, the mean
parasite prevalence remained similarly high [26]. In fact,
parasite prevalence was not meaningfully reduced until
the annual EIR was well below one infectious bite per per-
son per year. The high parasite prevalence despite low EIR
is multifactorial. Some plausible reasons include recurrent
infections due to Plasmodium vivax and Plasmodium
ovale, lack of access to care resulting in delayed treatment,
asymptomatic carriers, and frequent anti-malarial stock-
outs [27]. This epidemiological context likely accounts for
the high re-infection rates observed in this study, despite a
large reduction in EIR over the past two decades.
Both drug regimens were well tolerated with a low fre-
quency of vomiting. Although the frequency of vomiting
the first dose was similar between the two treatment arms,
only those in the DP arm (n = 3) vomited the drug twice
and required alternative treatment. Increased vomiting in
children aged six to 24 months with uncomplicated mal-
aria treated with DP, compared to AL, has been noted pre-
viously [28]. Vomiting did not seem to be related to
younger age in either group. However, this study was not
powered to detect such a difference.
There are a few limitations to this study. First, the even-
ing doses of AL were not directly observed. Although
caregivers were asked to confirm administration of even-
ing doses and children who missed doses were withdrawn,
the efficacy of AL may be underestimated in this study if
some missed doses were not reported. Similar studies have
used the same approach [29]. However, PCR-corrected ef-
ficacy of AL was still high in this study. In addition, PCR
data are missing for some children with treatment failure.
Nevertheless, as recrudescence was responsible for <10%
of failures in both arms, the ACPRs calculated considering
only available PCR samples are likely accurate. Also, para-
sitaemia range for study inclusion was altered to include
all children with P. falciparum mono-infection. This in-
creased the risk of including false positives; however, only
certified microscopists read slides and only nine subjects
had parasitaemia <2,000 parasites/μL. Lastly, contrary to
the original protocol, two months after initiation of re-
cruitment, study staff excluded some children with any
history of vomiting. The number of children excluded for
this reason is unknown, as only persistent vomiting was
an original exclusion criterion. Therefore, this study may
underestimate the incidence of vomiting associated with
the treatment regimens, as well as inadvertently excluding
some children with high parasitaemia or high fever.
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ting because the long half-life of piperaquine is associ-
ated with a decreased re-infection rate in the first
28 days after treatment compared to AL. This longer
prophylactic effect may allow more time for Hb recov-
ery, thus decreasing the severity of re-infections. The
once-a-day dosing is another advantage of this regimen
and may improve adherence. However, the higher cost
of a treatment dose of DP compared to AL, US$4 and
US$1, respectively, may be a barrier to its use as first
line. In addition, DP may be more prone to the develop-
ment of resistance because of the long half-life of
piperaquine.
Conclusions
The results of this study demonstrate that AL and DP
remain efficacious treatment regimens for uncompli-
cated P. falciparum malaria in western Kenya. With day
3 parasite clearance rates of nearly 100%, there is no evi-
dence of delayed parasite clearance to indicate emerging
artemisinin resistance. Following WHO recommenda-
tions, regular monitoring to evaluate anti-malarial efficacy
at least every two years should be maintained to confirm
the continued efficacy of first-line anti-malarial therapy.
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